KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Non-Current Assets (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Non-Current Assets for 9 consecutive years, with -$404.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 690.7% year-over-year to -$404.3 million, compared with a TTM value of -$664.3 million through Dec 2025, down 353.22%, and an annual FY2025 reading of -$404.3 million, down 690.7% over the prior year.
  • Non-Current Assets was -$404.3 million for Q4 2025 at Biocryst Pharmaceuticals, down from -$398.5 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $109.0 million in Q2 2024 and bottomed at -$404.3 million in Q4 2025.
  • Average Non-Current Assets over 3 years is -$35.6 million, with a median of $20.8 million recorded in 2024.
  • The sharpest move saw Non-Current Assets surged 478.69% in 2024, then tumbled 690.7% in 2025.
  • Year by year, Non-Current Assets stood at $21.0 million in 2023, then soared by 226.06% to $68.5 million in 2024, then crashed by 690.7% to -$404.3 million in 2025.
  • Business Quant data shows Non-Current Assets for BCRX at -$404.3 million in Q4 2025, -$398.5 million in Q2 2025, and $70.1 million in Q1 2025.